# Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

> **NCT03296696** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 30 (actual)

## Conditions studied

- Glioblastoma or Malignant Glioma

## Interventions

- **DRUG:** AMG 596
- **DRUG:** AMG 404

## Key facts

- **NCT ID:** NCT03296696
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-18
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-08-28
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** Amgen business decision
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03296696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03296696, "Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03296696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*